Infectious disease
AstraZeneca reported that its Phase III KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall survival (OS) compared to the EXTREME treatment regimen, which was chemotherapy plus cetuximab, a standard of care.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
Johnson & Johnson’s Janssen Biotech submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) for its single-dose COVID-19 vaccine.
Studies suggest the severity of COVID-19 infection may be lessened by flu vaccine.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
On the other hand, when dealing with a novel coronavirus, a certain amount of speed and urgency is necessary. Professor Chris Molloy, Chief Executive Officer of the U.K,’s Medicines Discovery Catapult, told BioSpace that real-time data should be considered, with a different lens applied.
The University of Oxford in the U.K., with the National Immunisation Schedule Evaluation Consortium, is planning a trial to evaluate the use of first and second doses of different COVID-19 vaccines.
A few companies shared some big Phase III results this week. Here’s a look.
The vast majority of COVID-19 vaccines on the market or in development are administered through an injection, but Vaxart is attempting to develop an oral vaccine.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
PRESS RELEASES